ABBV vs NVDA: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and NVIDIA Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
AbbVie Inc. Β· Healthcare
$208.05
+4.5% upside to fair value
Grade C High Quality
VS
NVIDIA Corporation Β· Technology
$182.08
+59.3% upside to fair value
High Conviction Grade A-
QuantHub Verdict
NVDA has more upside to fair value (+59.3%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ABBV NVDA
Current Price $208.05 $182.08
Fair Value Estimate $217.50 $290.00
Upside to Fair Value +4.5% +59.3%
Market Cap $367.9B $4,425.5B
Forward P/E 14.9x β€”
EV / EBITDA 16.7x 31.4x
Price / Sales 6.1x 21.0x
Price / FCF 20.9x 46.9x
Revenue Growth YoY +8.6% +65.5%
Gross Margin 83.7% 71.1%
Operating Margin 34.7% 60.4%
Return on Equity -129.24% 76.3%
Dividend Yield 3.2% 0.02%
FCF Yield 4.78% 2.13%
Analyst Consensus Buy Strong Buy
Investment Thesis
ABBV β€” AbbVie Inc.
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
NVDA β€” NVIDIA Corporation
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x v…
Accumulation Zones
Metric ABBV NVDA
Zone Low $163.13 $218.00
Zone High $184.88 $250.00
In Buy Zone? No Yes
← ABBV Research    NVDA Research β†’    All Research